Anemia Clinical Trial
Official title:
A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients
This is a prospective single-arm open-labeled cohort study on dialysis patients of the conversion from Aranesp® to NESP® for the treatment of anemia. The primary outcome of the study is the haemoglobin level after conversion to NESP® after 6 months. Secondary outcomes include the variability in haemoglobin level, average weekly dose of erythropoietin, safety profile of NESP®, patients' subjective assessment of fatigue and injection pain after the conversion.
Currently in Hong Kong, Aranesp®, manufactured by Amgen® is the only available Darbepoetin
alpha licensed. NESP®, a Darbepoetin alpha agent manufactured by Kirin®, will be replacing
Aranesp®.It is important to evaluate the therapeutic equivalence of the two agents, and its
efficacy, tolerability and safety profile in the treatment of anemia in dialysis patients.
Moreover, a new maximum preparation of NESP 120® microgram will be available to replace the
Aranesp® 100 microgram prefilled syringe at the same cost. This larger Darbepoetin alpha
preparation may allow extension of dosing intervals. This may subsequently allow cost saving
and better convenience to medical staff and patients.
The objectives of this project are:
1. To investigate the effectiveness of NESP® in the achieving a stable anemia control in
chronic dialysis patients with the same dose conversion from Aranesp®
2. To investigate the effectiveness of increasing the dosing interval of NESP® (but
maintaining the same total dose) in sustaining a stable anemia control in chronic
dialysis patients
3. To explore the possibility of cost saving in administering a larger dose NESP® but at an
extended interval
Patients will be divided into 3 groups.
Group A. Same dose conversion group
• Patients on stable low dose Aranesp® (on 20mcg preparations or on 40mcg every 2 weeks
or less) will be converted to the same dose of NESP®
Group B. Attempt extension of dosing interval with higher dose of NESP® preparations
• Patients on stable dose of Aranesp® will be converted to higher dose preparation of
NESP® (40 or 120 mcg preparations) with extended dosing intervals.
Group C. Attempt dosage saving with 120 mcg preparation
• Patients on Aranesp® 100mcg will be switched to the NESP® 120mcg preparation with
slight increase in dosing interval
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Active, not recruiting |
NCT02101944 -
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |